Skip to content

Emergent Biosolutions EBS PP&E Sale Proceeds

PP&E Sale Proceeds at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$0-100%
Opko Health logo
Opko HealthOPK
$33K-50.7%

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's pp&e sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's PP&E sale proceeds?
Emergent Biosolutions (EBS) reported PP&E sale proceeds of $0 in Q1 2026.
How has Emergent Biosolutions's PP&E sale proceeds changed year-over-year?
Emergent Biosolutions's PP&E sale proceeds decreased by 100.0% year-over-year, from $38.1M to $0.
What does PP&E sale proceeds mean?
Cash received from selling property, plant, and equipment no longer needed for operations.